A Phase I/II, First-in-Human, Open-Label, Dose Escalation Study of ZL-1211 in Patients with Unresectable or Metastatic Solid Tumor
A Phase I/II, First-in-Human, Open-Label, Dose Escalation Study of ZL-1211 in Patients with Unresectable or Metastatic Solid Tumor
Learn more about our Cancer Treatment Team by scrolling below, or visit our Meet the Team page.